Literature DB >> 24165439

The hows and whys of constructing a native recombinant cholera vaccine.

Mina Boustanshenas1, Bita Bakhshi1.   

Abstract

Emergence of different ctxB genotypes within virulent Vibrio cholerae populations accentuates the need to develop a vaccine that has the potential to protect against all cholera toxin genotypes. Oral administration of rCTB-alone and in combination with 2 dominant domestic killed whole cells of V. cholerae (O1 Ogawa El Tor and O1 Inaba El Tor) plus one standard V. cholerae (O1 Ogawa classic ATCC 14035)-has shown satisfactory protection as a potent vaccine candidate against toxigenic V. cholerae.

Entities:  

Keywords:  Vibrio cholerae; cholera toxin; native vaccine; rabbit; recombinant CTB

Mesh：

Substances：

Year:  2013        PMID： 24165439      PMCID： PMC4008468          DOI： 10.4161/bioe.26420

Source DB:  PubMed          Journal:  Bioengineered        ISSN： 2165-5979            Impact factor:   3.269


  25 in total

1.  Intestinal antibody responses after immunisation with cholera B subunit.

Authors:  A M Svennerholm; D A Sack; J Holmgren; P K Bardhan
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

Review 2.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

3.  Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.

Authors:  N Goto; J Maeyama; Y Yasuda; M Isaka; K Matano; S Kozuka; T Taniguchi; Y Miura; K Ohkuma; K Tochikubo
Journal:  Vaccine       Date:  2000-04-14       Impact factor: 3.641

Review 4.  Cholera vaccines.

Authors:  E T Ryan; S B Calderwood
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

5.  IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin.

Authors:  M R Fontana; E Monaci; L Yanqing; Q Guoming; G Duan; R Rappuoli; M Pizza
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

6.  The expression of biologically active cholera toxin in Escherichia coli.

Authors:  M L Gennaro; P J Greenaway; D A Broadbent
Journal:  Nucleic Acids Res       Date:  1982-08-25       Impact factor: 16.971

Review 7.  Cholera.

Authors:  David A Sack; R Bradley Sack; G Balakrish Nair; A K Siddique
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321

8.  Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6XHis-tagged protein in Escherichia coli.

Authors:  Ana Paula de Mattos Arêas; Maria Leonor Sarno de Oliveira; Celso Raul Romero Ramos; Maria Elisabete Sbrogio-Almeida; Isaías Raw; Paulo Lee Ho
Journal:  Protein Expr Purif       Date:  2002-08       Impact factor: 1.650

9.  Field trial of oral cholera vaccines in Bangladesh.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; B F Stanton; B A Kay; M U Khan; M Yunus; W Atkinson
Journal:  Lancet       Date:  1986-07-19       Impact factor: 79.321

10.  Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; P K Neogy; B Stanton; N Huda; M U Khan; B A Kay; M R Khan
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.